-
Nov 12, 2024 | 
nature.com | Douglas Tremblay |Clifford M. Csizmar |Courtney DiNardo |Danielle Hammond |Tapan M Kadia |Farhad Ravandi | +10 more
Chronic myelomonocytic leukemia (CMML) is a rare hematologic malignancy with overlapping features of myelodysplastic neoplasm (MDS) and myeloproliferative neoplasms characterized by peripheral blood monocytosis [1]. There is a predisposition for transformation to acute myeloid leukemia (AML), termed CMML with blast transformation (CMML-BT) [2, 3].
-
Sep 12, 2024 | 
hmpgloballearningnetwork.com | John Mascarenhas
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, New York, shares highlights from a discussion on the utilization and selection of optimal JAK inhibitor therapies for the treatment of patients with myelofibrosis (MF). This research was presented at the 2024 Annual Society of Hematologic Oncology (SOHO) meeting in Houston, Texas. Transcript:I'm John Mascarenhas from the Icahn School of Medicine at Mount Sinai.
-
Jul 8, 2024 | 
targetedonc.com | John Mascarenhas
John Mascarenhas, MD, professor, medicine, Icahn School of Medicine, Mount Sinai, director, Center of Excellence for Blood Cancers and Myeloid Disorders, member, The Tisch Cancer Institute, Mount Sinai, discusses the methods, design, and inclusion criteria of the phase 3 SENTRY trial (NCT04562389) for patients with JAK inhibitor treatment-naive myelofibrosis.
-
Jun 21, 2024 | 
onclive.com | John Mascarenhas
-
Jun 7, 2024 | 
targetedonc.com | John Mascarenhas
John Mascarenhas, MD, professor, medicine, Icahn School of Medicine, Mount Sinai, director, Center of Excellence for Blood Cancers and Myeloid Disorders, member, The Tisch Cancer Institute, Mount Sinai, discusses phase 3 of the SENTRY (NCT04562389) trial, a global, multicenter, phase 1/3 study evaluating the efficacy and safety of selinexor (Xpovio) when given in combination with ruxolitinib (Jakafi) in patients with JAK inhibitor treatment-naive myelofibrosis.
-
Mar 15, 2024 | 
newsbreak.com | John Mascarenhas
Welcome to NewsBreak, an open platform where diverse perspectives converge. Our contributor network of tens of thousands of creators appears alongside stories from established publications and journalists. We empower individuals to share insightful viewpoints through short posts and comments. It’s essential to note our commitment to transparency: our Terms of Use acknowledge that our services may not always be error-free, and our Community Standards emphasize our discretion in enforcing policies.
-
Mar 15, 2024 | 
newsbreak.com | John Mascarenhas
Welcome to NewsBreak, an open platform where diverse perspectives converge. Our contributor network of tens of thousands of creators appears alongside stories from established publications and journalists. We empower individuals to share insightful viewpoints through short posts and comments. It’s essential to note our commitment to transparency: our Terms of Use acknowledge that our services may not always be error-free, and our Community Standards emphasize our discretion in enforcing policies.
-
Mar 15, 2024 | 
targetedonc.com | John Mascarenhas
Case: A 62-Year-Old Man with MyelofibrosisClinical Presentation:A 62-year-old man presented with symptoms of fatigue, night sweats, and increased bruising. PMH: type 2 diabetes, hypercholesteremia, and hypertension1 year prior, patient had a “normal” physical and blood work. PCP noticed lower Hg (11 to 9.5 g/dL) and Plt (350 to 195 cells/m3)Patient was referred to Hem/Onc – first available appoint in 2 months.
-
Feb 1, 2024 | 
onclive.com | John Mascarenhas
February 1, 2024 Supplements And Featured PublicationsReviewing Research Efforts Seeking to Raise the Bar in Myelofibrosis John Mascarenhas, MD, discusses the use of selinexor with ruxolitinib in JAK inhibitor–naive myelofibrosis, highlighting the phase 2 XPORT-MF-044 trial John Mascarenhas, MD, professor, medicine, Icahn School of Medicine, Mount Sinai, director, Center of Excellence for Blood Cancers and Myeloid Disorders, member, The Tisch Cancer Institute, Mount Sinai, discusses the use...
-
Jan 3, 2024 | 
onclive.com | John Mascarenhas
John Mascarenhas, MD, professor of medicine, Icahn School of Medicine, Mount Sinai, director, Center of Excellence for Blood Cancers and Myeloid Disorders, member, the Tisch Cancer Institute, Mount Sinai, discusses the potential advantages of utilizing selinexor (Xpovio) with ruxolitinib (Jakafi) in patients with JAK inhibitor–naive myelofibrosis.
